Hyun Mi Kim, Ki Tae Kwon, Hyun-Hwa Cha, Won Joon Seong, Mi Ju Kim
{"title":"2019冠状病毒病妊娠晚期妇女不良结局预测","authors":"Hyun Mi Kim, Ki Tae Kwon, Hyun-Hwa Cha, Won Joon Seong, Mi Ju Kim","doi":"10.3947/ic.2022.0065","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to compare the clinical and laboratory characteristics of two groups of women (favorable and adverse outcome groups) in the third trimester of pregnancy with coronavirus disease 2019 (COVID-19) and to investigate the predictors of specific adverse outcomes.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed the medical records of patients hospitalized with COVID-19 between November 2020 and October 2021 at Kyungpook National University Chilgok Hospital. Adverse outcomes were clinically defined using the Novel Coronavirus Pneumonia Emergency Response Epidemiology Team criteria. The group without adverse outcomes was defined as the \"favorable outcome\" group and the rest as the \"adverse outcome\" group. We compared the clinical characteristics between the two groups and examined the correlation between their laboratory results and adverse outcomes.</p><p><strong>Results: </strong>Of the 70 pregnant women included, 37 were in their third trimester. No significant differences in clinical characteristics, except the length of hospitalization, were noted between the groups. In laboratory tests conducted immediately after hospitalization, C-reactive protein (CRP) (1.0 [0.3 - 1.4] <i>vs.</i> 2.3 [1.3 - 3.6], <i>P</i> = 0.001) and ferritin (25.0 [14.5 - 34.5] <i>vs.</i> 53.1 [36.0 - 98.0], <i>P</i> <0.03) levels were significantly different between the groups. Logistic regression analysis revealed that CRP (odds ratio [OR]: 2.26; 95% confidence interval [CI]: 1.09 - 5.51, <i>P</i> = 0.040) and ferritin (OR: 1.06; 95% CI: 1.01 - 1.15, <i>P</i> = 0.047) levels were predictors of adverse outcomes.</p><p><strong>Conclusion: </strong>CRP and ferritin levels are associated with poor prognosis and can predict adverse outcomes in women with COVID-19 in the third trimester of pregnancy.</p>","PeriodicalId":520645,"journal":{"name":"Infection & chemotherapy","volume":" ","pages":"493-503"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/1f/ic-54-493.PMC9533151.pdf","citationCount":"2","resultStr":"{\"title\":\"Prediction of Adverse Outcomes among Women in the Third Trimester of Pregnancy with Coronavirus Disease 2019.\",\"authors\":\"Hyun Mi Kim, Ki Tae Kwon, Hyun-Hwa Cha, Won Joon Seong, Mi Ju Kim\",\"doi\":\"10.3947/ic.2022.0065\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study aimed to compare the clinical and laboratory characteristics of two groups of women (favorable and adverse outcome groups) in the third trimester of pregnancy with coronavirus disease 2019 (COVID-19) and to investigate the predictors of specific adverse outcomes.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed the medical records of patients hospitalized with COVID-19 between November 2020 and October 2021 at Kyungpook National University Chilgok Hospital. Adverse outcomes were clinically defined using the Novel Coronavirus Pneumonia Emergency Response Epidemiology Team criteria. The group without adverse outcomes was defined as the \\\"favorable outcome\\\" group and the rest as the \\\"adverse outcome\\\" group. We compared the clinical characteristics between the two groups and examined the correlation between their laboratory results and adverse outcomes.</p><p><strong>Results: </strong>Of the 70 pregnant women included, 37 were in their third trimester. No significant differences in clinical characteristics, except the length of hospitalization, were noted between the groups. In laboratory tests conducted immediately after hospitalization, C-reactive protein (CRP) (1.0 [0.3 - 1.4] <i>vs.</i> 2.3 [1.3 - 3.6], <i>P</i> = 0.001) and ferritin (25.0 [14.5 - 34.5] <i>vs.</i> 53.1 [36.0 - 98.0], <i>P</i> <0.03) levels were significantly different between the groups. Logistic regression analysis revealed that CRP (odds ratio [OR]: 2.26; 95% confidence interval [CI]: 1.09 - 5.51, <i>P</i> = 0.040) and ferritin (OR: 1.06; 95% CI: 1.01 - 1.15, <i>P</i> = 0.047) levels were predictors of adverse outcomes.</p><p><strong>Conclusion: </strong>CRP and ferritin levels are associated with poor prognosis and can predict adverse outcomes in women with COVID-19 in the third trimester of pregnancy.</p>\",\"PeriodicalId\":520645,\"journal\":{\"name\":\"Infection & chemotherapy\",\"volume\":\" \",\"pages\":\"493-503\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/1f/ic-54-493.PMC9533151.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection & chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3947/ic.2022.0065\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection & chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2022.0065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
背景:本研究旨在比较两组(有利和不良结局组)妊娠晚期冠状病毒病2019 (COVID-19)妇女的临床和实验室特征,并探讨特定不良结局的预测因素。材料和方法:我们回顾性分析了2020年11月至2021年10月在庆北大学漆谷医院住院的COVID-19患者的病历。不良后果的临床定义采用新型冠状病毒肺炎应急流行病学小组标准。没有不良结果的组被定义为“良好结果”组,其余的被定义为“不良结果”组。我们比较了两组的临床特征,并检查了他们的实验室结果与不良后果之间的相关性。结果:在纳入的70名孕妇中,37名处于妊娠晚期。除住院时间外,两组间的临床特征无显著差异。在住院后立即进行的实验室检测中,c -反应蛋白(CRP) (1.0 [0.3 - 1.4] vs. 2.3 [1.3 - 3.6], P = 0.001)和铁蛋白(25.0 [14.5 - 34.5]vs. 53.1 [36.0 - 98.0], P = 0.040)和铁蛋白(OR: 1.06;95% CI: 1.01 - 1.15, P = 0.047)水平是不良结局的预测因子。结论:CRP和铁蛋白水平与妊娠晚期COVID-19患者预后不良相关,可预测不良结局。
Prediction of Adverse Outcomes among Women in the Third Trimester of Pregnancy with Coronavirus Disease 2019.
Background: This study aimed to compare the clinical and laboratory characteristics of two groups of women (favorable and adverse outcome groups) in the third trimester of pregnancy with coronavirus disease 2019 (COVID-19) and to investigate the predictors of specific adverse outcomes.
Materials and methods: We retrospectively reviewed the medical records of patients hospitalized with COVID-19 between November 2020 and October 2021 at Kyungpook National University Chilgok Hospital. Adverse outcomes were clinically defined using the Novel Coronavirus Pneumonia Emergency Response Epidemiology Team criteria. The group without adverse outcomes was defined as the "favorable outcome" group and the rest as the "adverse outcome" group. We compared the clinical characteristics between the two groups and examined the correlation between their laboratory results and adverse outcomes.
Results: Of the 70 pregnant women included, 37 were in their third trimester. No significant differences in clinical characteristics, except the length of hospitalization, were noted between the groups. In laboratory tests conducted immediately after hospitalization, C-reactive protein (CRP) (1.0 [0.3 - 1.4] vs. 2.3 [1.3 - 3.6], P = 0.001) and ferritin (25.0 [14.5 - 34.5] vs. 53.1 [36.0 - 98.0], P <0.03) levels were significantly different between the groups. Logistic regression analysis revealed that CRP (odds ratio [OR]: 2.26; 95% confidence interval [CI]: 1.09 - 5.51, P = 0.040) and ferritin (OR: 1.06; 95% CI: 1.01 - 1.15, P = 0.047) levels were predictors of adverse outcomes.
Conclusion: CRP and ferritin levels are associated with poor prognosis and can predict adverse outcomes in women with COVID-19 in the third trimester of pregnancy.